CJC-1295 and Ipamorelin are two research peptides studied for their complementary roles in growth hormone signaling. Preclinical research suggests this stack may support pulsatile GH release via distinct receptor pathways. Access is subject to medical approval by a licensed provider at TelosRX.
Growth hormone naturally declines with age. Researchers have explored peptide-based approaches to support this decline without directly replacing growth hormone itself.
CJC-1295 and Ipamorelin represent two such compounds. They are frequently studied in combination due to their synergistic mechanisms.
What Is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland.
Preclinical research suggests it promotes endogenous growth hormone release. A modified form (CJC-1295 with DAC) has an extended half-life compared to native GHRH.
Neither form is FDA-approved for clinical use outside of investigational contexts.
What Is Ipamorelin?
Ipamorelin is a selective growth hormone secretagogue (GHSR agonist). It acts on ghrelin receptors to stimulate pulsatile GH release.
Research interest in Ipamorelin centers on its selectivity. Studies suggest it does not significantly elevate cortisol or prolactin at standard research doses — a distinction from earlier secretagogues like GHRP-6.
Ipamorelin is not FDA-approved.
Why These Peptides Are Studied Together
CJC-1295 and Ipamorelin act through different but complementary pathways. CJC-1295 stimulates the GHRH receptor; Ipamorelin acts on the ghrelin/GHSR receptor.
Preclinical data suggests the combination produces synergistic GH pulses. This dual-receptor approach is a central reason researchers examine the stack rather than either compound alone.
| Compound | Receptor Target | Mechanism | Regulatory Status |
|---|---|---|---|
| CJC-1295 | GHRH receptor | Stimulates pituitary GH release | Not FDA-approved |
| Ipamorelin | Ghrelin / GHSR receptor | Selective GH secretagogue | Not FDA-approved |
Preclinical Research Highlights
Animal studies and early human research have explored several potential areas of interest for this peptide combination:
- Growth hormone pulsatility: Research suggests the combination supports natural pulsatile GH patterns rather than continuous elevation.
- IGF-1 activity: GH stimulation is linked downstream to IGF-1 production, studied in contexts of tissue repair and metabolic signaling.
- Recovery science: Preclinical models have explored GH secretagogue effects on protein synthesis and tissue repair timelines.
- Body composition research: Early studies examined relationships between GH signaling and lean mass maintenance.
- Sleep quality: Some research has explored GH secretagogue effects during deep sleep phases, when natural GH pulses peak.
These findings are preliminary. Human clinical trials are limited. Individual results vary and are not guaranteed.
How Telehealth Evaluation Works at TelosRX
TelosRX is an online-first, asynchronous telehealth service. There are no in-person visits or real-time appointments required.
The evaluation process is straightforward:
- Submit your health intake form online — on your schedule.
- A licensed provider reviews your information asynchronously.
- If medically appropriate, a provider-issued prescription is generated.
- Compounded peptides are shipped directly to you.
Approval is not guaranteed. All access is subject to medical approval by a licensed provider.
Who May Be a Candidate
Individuals who ask about CJC-1295 and Ipamorelin through TelosRX typically include:
- Adults concerned about age-related decline in growth hormone output
- Those exploring recovery support after training or injury
- People interested in longevity and metabolic health research
- Patients who have discussed GH optimization with their physician
A provider evaluation is required to determine if this protocol is appropriate for you.
Important Safety and Regulatory Notes
CJC-1295 and Ipamorelin are not FDA-approved for any indication. They are available through licensed compounding pharmacies under federal compounding regulations.
Known research considerations include monitoring for:
- Water retention, particularly at higher doses in animal studies
- Transient changes in blood glucose related to IGF-1 activity
- Potential interactions with other hormonal therapies (e.g., TRT or thyroid support)
Long-term human safety data is limited. These compounds are prepared under federal compounding regulations and not manufactured as FDA-approved drug products.
CJC-1295 and Ipamorelin are not FDA-approved compounds. They are prepared under federal compounding regulations. Approval is not guaranteed. Individual results vary. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.
Start your private evaluation at TelosRX.